Sun Pharma launches Novel Drug Kapspargo Sprinkle in USA

06 Aug 2018 Evaluate

Sun Pharmaceutical Industries has launched Kapspargo Sprinkle (metoprolol succinate) extended-release capsules in the US, for the treatment of hypertension (to lower blood pressure), angina pectoris (chest pain), and heart failure (to reduce the risk of cardiovascular mortality and heart-failure hospitalization in patients with heart failure).

Kapspargo Sprinkle, a US Food and Drug Administration (USFDA) approved, novel, patented formulation of metoprolol succinate, is the first and only extended-release sprinkle formulation of this beta1-selective adrenoreceptor blocking agent (beta-blocker). It is covered by United States Patent numbers 9,504,655 and 9,700,530, expiring Jul 09, 2035.

Kapspargo Sprinkle pellets can be sprinkled over soft food (such as applesauce, yogurt or pudding) or administered via a nasogastric tube, and are designed to facilitate long-term, once-daily administration, particularly for patients who have difficulty swallowing.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharma Inds. Share Price

1670.80 -29.75 (-1.75%)
16-Jan-2026 12:52 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.80
Dr. Reddys Lab 1187.65
Cipla 1399.90
Zydus Lifesciences 879.10
Lupin 2196.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×